Evidence map›Paper›PMID 42399078›Full record

ArticleRMD open2026

Beyond genotype: clustering analysis highlights clinical heterogeneity in paediatric familial Mediterranean fever.

Isild Mahé, Claire Billard, Federica Anselmi, Linda Rossi-Semerano, Caroline Galeotti, Isabelle Kone-Paut, Perrine Dusser

Abstract read
In one paragraph

Article in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Isild MahéPaediatric Rheumatology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux universitaires Paris-Sud - Hôpital Bicêtre, Paris, France.ORCID http://orcid.org/0009-0003-6646-2216
Claire BillardInferential Premium Biometry, Paris, France.
Federica AnselmiPaediatric Rheumatology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux universitaires Paris-Sud - Hôpital Bicêtre, Paris, France.ORCID http://orcid.org/0000-0001-6796-6385
Linda Rossi-SemeranoPaediatric Rheumatology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux universitaires Paris-Sud - Hôpital Bicêtre, Paris, France.
Caroline GaleottiPaediatric Rheumatology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux universitaires Paris-Sud - Hôpital Bicêtre, Paris, France.
Isabelle Kone-PautPaediatric Rheumatology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux universitaires Paris-Sud - Hôpital Bicêtre, Paris, France.ORCID http://orcid.org/0000-0001-8939-5763
Perrine DusserPaediatric Rheumatology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux universitaires Paris-Sud - Hôpital Bicêtre, Paris, France perrine.dusser@aphp.fr.ORCID http://orcid.org/0000-0001-8118-0848

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFamilial Mediterranean fever (FMF) is an autoinflammatory disease caused by mutations in the

objectivesTo identify clinically meaningful subgroups of paediatric patients with FMF using a clustering approach and to characterise their clinical features and disease trajectories.

methodsWe conducted a monocentric retrospective study including 185 paediatric patients diagnosed with FMF between 2004 and 2025 according to Eurofever criteria. Patients were stratified as genetically confirmed FMF (homozygous, compound heterozygous) or symptomatic heterozygotes. Demographic, clinical, laboratory and treatment data were collected longitudinally. Clustering analysis was used to identify clinically meaningful subgroups.

resultsThe median age at onset was 2.5 years and the median diagnostic delay was 24 months. Ninety-three (50%) patients were symptomatic heterozygotes. Compared with genetically confirmed FMF, heterozygotes had milder disease, lower colchicine doses and less frequent IL-1 inhibitor use. Cluster analysis identified five distinct subgroups, ranging from asymptomatic or mild heterozygotes without treatment to early-onset homozygous patients with severe disease requiring higher-dose colchicine and IL-1 inhibitors. Not all heterozygous patients had a mild disease course. Sex, age at onset, genotype, attack frequency and inflammatory markers contributed to cluster differentiation. Severe phenotypes were enriched in female patients with early-onset M694V homozygosity.

conclusionCluster analysis identified heterogeneous patterns of disease expression, suggesting that the genotype alone does not fully explain clinical variability in FMF. These findings highlight the value of multidimensional approaches to better characterise disease heterogeneity.

Indexed as

Familial Mediterranean FeverGenotypeAdolescentAge of OnsetChildChild, PreschoolCluster AnalysisClustering AlgorithmsColchicineFemaleGenetic Association StudiesGenetic Predisposition to DiseaseHeterozygoteHomozygoteHumansInfantColchicineMEFV protein, humanPyrinChildFamilial Mediterranean FeverRare DiseasesRisk Factors

Identifiers

PMID42399078
PMCPMC13343110

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.